Morgan Stanley Downgrades BioAge Labs to Underweight From Overweight, Slashes Price Target to $5 From $40
Citigroup Downgrades BioAge Labs to Neutral From Buy, Adjusts Price Target to $7 From $45
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40
Bioage Labs Analyst Ratings
Jefferies Downgrades Bioage Labs to Hold, Lowers Price Target to $7
Analysts Offer Insights on Healthcare Companies: BioAge Labs, Inc. (BIOA), Acadia Healthcare (ACHC) and Bicara Therapeutics Inc. (BCAX)
Morgan Stanley Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley Keeps Their Buy Rating on BioAge Labs, Inc. (BIOA)
Citi Maintains BioAge Labs(BIOA.US) With Buy Rating, Maintains Target Price $45
Citi Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $45
Bioage Labs Analyst Ratings
Jefferies Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $42
Morgan Stanley Initiates BioAge Labs(BIOA.US) With Buy Rating, Announces Target Price $40
BioAge Labs Initiated With an Overweight at Morgan Stanley
BioAge Labs Initiated With a Buy at Jefferies
BioAge Labs, Inc.: Promising Developments and Strategic Partnerships Lead to Buy Rating
No Data